Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Leyre Mestre

Showing results (1-10 of 37) with videos related to

Pageof 4
Sort By:
British Journal of Pharmacology|April 12, 2005
Activation of cannabinoid CB2 receptor negatively regulates IL-12p40 production in murine macrophages: role of IL-10 and ERK1/2 kinase signalingFernando Correa, Leyre Mestre, Fabian Docagne, et al.
Biochemical Pharmacology|August 18, 2006
The synthetic cannabinoid WIN 55,212-2 increases COX-2 expression and PGE2 release in murine brain-derived endothelial cells following Theiler's virus infectionLeyre Mestre, Fernando Correa, Fabian Docagne, et al.
Vitamins and Hormones|August 4, 2009
The endocannabinoid anandamide from immunomodulation to neuroprotection. Implications for multiple sclerosisFernando G Correa, Leyre Mestre, Fabián Docagne, et al.
International Journal of Molecular Sciences|November 26, 2022
The Dual PDE7-GSK3β Inhibitor, VP3.15, as Neuroprotective Disease-Modifying Treatment in a Model of Primary Progressive Multiple SclerosisRocio Benítez-Fernández, Carmen Gil, Carmen Guaza, et al.
Expert Opinion on Therapeutic Targets|January 23, 2008
Therapeutic potential of CB2 targeting in multiple sclerosisFabian Docagne, Leyre Mestre, Frida Loría, et al.
Frontiers in Cellular Neuroscience|March 7, 2020
Perspectives on Cannabis-Based Therapy of Multiple Sclerosis: A Mini-ReviewMiriam Mecha, Francisco J Carrillo-Salinas, Ana Feliú, et al.
Progress in Neurobiology|December 4, 2012
Viral models of multiple sclerosis: neurodegeneration and demyelination in mice infected with Theiler's virusMiriam Mecha, Francisco J Carrillo-Salinas, Leyre Mestre, et al.
The Biochemical Journal|October 27, 2007
Anandamide inhibits IL-12p40 production by acting on the promoter repressor element GA-12: possible involvement of the COX-2 metabolite prostamide E(2)Fernando Correa, Fabian Docagne, Diego Clemente, et al.
Brain, Behavior, and Immunity|February 12, 2011
The endocannabinoid anandamide downregulates IL-23 and IL-12 subunits in a viral model of multiple sclerosis: evidence for a cross-talk between IL-12p70/IL-23 axis and IL-10 in microglial cellsFernando Correa, Miriam Hernangómez-Herrero, Leyre Mestre, et al.
Neuroimmunomodulation|December 13, 2007
Cannabinoid system and neuroinflammation: implications for multiple sclerosisFernando Correa, Fabian Docagne, Leyre Mestre, et al.
Pageof 4

Showing results (1-10 of 37) with videos related to

Sort By:
Pageof 4
British Journal of Pharmacology|April 12, 2005
Activation of cannabinoid CB2 receptor negatively regulates IL-12p40 production in murine macrophages: role of IL-10 and ERK1/2 kinase signalingFernando Correa, Leyre Mestre, Fabian Docagne, et al.
Biochemical Pharmacology|August 18, 2006
The synthetic cannabinoid WIN 55,212-2 increases COX-2 expression and PGE2 release in murine brain-derived endothelial cells following Theiler's virus infectionLeyre Mestre, Fernando Correa, Fabian Docagne, et al.
Vitamins and Hormones|August 4, 2009
The endocannabinoid anandamide from immunomodulation to neuroprotection. Implications for multiple sclerosisFernando G Correa, Leyre Mestre, Fabián Docagne, et al.
International Journal of Molecular Sciences|November 26, 2022
The Dual PDE7-GSK3β Inhibitor, VP3.15, as Neuroprotective Disease-Modifying Treatment in a Model of Primary Progressive Multiple SclerosisRocio Benítez-Fernández, Carmen Gil, Carmen Guaza, et al.
Expert Opinion on Therapeutic Targets|January 23, 2008
Therapeutic potential of CB2 targeting in multiple sclerosisFabian Docagne, Leyre Mestre, Frida Loría, et al.
Frontiers in Cellular Neuroscience|March 7, 2020
Perspectives on Cannabis-Based Therapy of Multiple Sclerosis: A Mini-ReviewMiriam Mecha, Francisco J Carrillo-Salinas, Ana Feliú, et al.
Progress in Neurobiology|December 4, 2012
Viral models of multiple sclerosis: neurodegeneration and demyelination in mice infected with Theiler's virusMiriam Mecha, Francisco J Carrillo-Salinas, Leyre Mestre, et al.
The Biochemical Journal|October 27, 2007
Anandamide inhibits IL-12p40 production by acting on the promoter repressor element GA-12: possible involvement of the COX-2 metabolite prostamide E(2)Fernando Correa, Fabian Docagne, Diego Clemente, et al.
Brain, Behavior, and Immunity|February 12, 2011
The endocannabinoid anandamide downregulates IL-23 and IL-12 subunits in a viral model of multiple sclerosis: evidence for a cross-talk between IL-12p70/IL-23 axis and IL-10 in microglial cellsFernando Correa, Miriam Hernangómez-Herrero, Leyre Mestre, et al.
Neuroimmunomodulation|December 13, 2007
Cannabinoid system and neuroinflammation: implications for multiple sclerosisFernando Correa, Fabian Docagne, Leyre Mestre, et al.
Pageof 4